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Current treatment of metastatic bone prostate cancer with Docetaxel chemotherapy per CHAARTED trial
is standard of care. Timing of CT and bone scintigraphy for evaluation of successful treatment of lytic
lesions is not available in the literature. We present a case of a 70 year old male with PSA of 586 and wide
spread metastatic bone lytic lesions, who underwent androgen deprivation therapy and six cycles of
Docetaxel chemotherapy. The patient had clinically successful treatment. Contrast enhanced CT scan
demonstrated sclerotic bone lesions with PSA 2.5 at this point in treatment; however, 99mTc-MDP bone
scintigraphy remained positive for metastatic lesions.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Current treatment of metastatic bone prostate cancer with
Docetaxel chemotherapy per CHAARTED trial is the standard of
care. Timing of bone scintigraphy for evaluation of successful
treatment of lytic lesions is not available in the literature. We pre-
sent a case with clinically successful treatment but positive bone
scan results 1 month after chemotherapy.Case presentation
A 70 year old male presented with prostate speciﬁc antigen
(PSA) of 586 and a baseline PSA of 3.7 a year prior. Biopsy and
staging: T4, G4þ3 prostate cancer with perineural invasion.
Staging contrast CT scan revealed wide spread lytic lesions(V.Y. Bird).
Inc. This is an open access article uwith large 11th rib and left ileum lytic lesions, bladder soft
tissue mass effect, and pelvic lymphadenopathy. 99mTc-MDP
bone scintigraphy showed multifocal lytic lesions with increased
blood pool/intense hyperemia activity at 5 minutes and 2 hours
after hydration, consistent with aggressive appearing lytic
metastatic disease. 11th rib biopsy was consistent with metastatic
prostate cancer. The patient underwent immediate androgen
deprivation therapy (ADT), 6 cycles of systemic Docetaxel, and
pelvis/pubic ramus radiation for bone pain palliation. He
had clinical improvement post-Docetaxel with PSA of 2.5
(Figs. 1 and 2).
One month follow up CT scan demonstrated sclerotic lesions
with minimal evidence of active metastatic disease; however bone
scan still showed multiple uptake areas consistent with active
disease. Current literature for hormone sensitive prostate cancer
with lytic bone lesions stems from breast cancer management; CT
scan in this patient provides evidence of successful treatment
suggested by sclerotic lesions as is seen in breast and prostate
cancer patients post-chemotherapy.1e3 However, there is no data
with timing recommendations for bone scan to evaluate successful
treatment outcome of prostate cancer with metastatic lytic lesions
(Fig. 3).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Composite photomicrograph showing the morphologic features of prostatic tissue. A) Low power view showing a prostate needle biopsy demonstrating back-to-back
glands with an inﬁltrative growth pattern, glandular fusion, and cribiform architecture (arrow) consistent with Gleason pattern 4 (H&E, original magniﬁcation 10). B) High po-
wer view showing the cribiform architecture and cytologic features. The tumor cells have large nuclei (arrow) with prominent large nucleoli (H&E, original magniﬁcation 10). C)
Prostatic adenocarcinoma with perineural invasion (arrow) in a core needle biopsy (H&E, original magniﬁcation 40).
Figure 2. A) Photomicrograph of the left rib core needle biopsy demonstrating met-
astatic prostate carcinoma involving bone; woven bone deposition (arrow) and novel
bone formation upon sites of prior resorption creating a marked reversal front
(arrowhead) appear consistent with a lesion exhibiting increased bone breakdown and
repair. H&E, original magniﬁcation 20. B (inset) Fine needle aspiration of left rib
lesion demonstrating positive immunoreactivity for prostate speciﬁc acid phosphatase
(PSAP) (immunohistochemistry, original magniﬁcation 40).
Figure 3. Pre-chemotherapy blood pool (A) and delay (C) shows increased uptake in th
chemotherapy blood pool (B) and delay (D) shows persistent, but decreased uptake on left
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There is no current determination for when bone scintigraphy
would become negative after Docetaxel therapy for lytic lesions.
Although current literature suggests repeat bone scans coupled
with PSA levels at 3 and 6 months following chemotherapy to
detect ﬂare phenomenon and repeat CT scans every 2e4 months
following Docetaxel therapy, there is no current consensus on the
timing of bone scintigraphy for evaluation of treatment response,
yet experts recommend that it be performed regularly.4,5 It is
increasingly recognized that techniques combining morphological
and functional data are the most sensitive and speciﬁc, with PET/CT
and PET/MRI emerging as important future tools.6 In our case, CT
scan provides evidence of clinical successful treatment by demon-
stration of sclerotic lesions; however, bone scintigraphy still depicts
active disease, a discrepancy that is consistent with treatment
response and the associated ﬂare phenomenon.1,3,4 Novel imaging-
based biomarkers such as function diffusion mapping are being
investigated for early evaluation of treatment response with
encouraging results that may even indicate greater utility fore left 11th rib corresponding to lytic metastasis on axial CT (E). One month pos
11th rib with positive post-treatment sclerosis on axial CT (F).t-
V.Y. Bird et al. / Urology Case Reports 6 (2016) 12e1414monitoring response to treatment in the setting of metastatic lytic
bone disease.2,7Conclusion
There is a need for speciﬁc radiographic studies to differentiate
between active metastatic bone lesion and active sclerotic
non-malignant bone lesion. While the literature describes many
new imaging methods, claiming increased sensitivity and speci-
ﬁcity, these have yet to be appropriately tested in clinical trials.5
Additionally, precise criteria are lacking for the identiﬁcation of
ﬂare phenomenon in response to treatment.Conﬂicts of interest
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